Evidence map›Paper›PMID 9665473›Full record

ArticleThe American journal of pathology1998

Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat.

S M Ho, I Leav, S Ghatak, F Merk, V S Jagannathan, K Mallery

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Estrogens and prostate cancer: etiology, mediators, prevention, and management.Endocrinology and metabolism clinics of North America · 2011
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Androgens and prostate cancer.World journal of urology · 2003
    Review
  9. Review
  10. Overexpression of clusterin in human breast carcinoma.The American journal of pathology · 2000
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

S M HoDepartment of Biology, Tufts University, Medford, Massachusetts 02155, USA.
I Leav
S Ghatak
F Merk
V S Jagannathan
K Mallery
Tufts University · US

Funding

PROSTATIC DIFFERENTIATION &SEX HORMONE METABOLISMR01CA015776 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HO, SHUK-MEI · 1987 to 2008
$1.8M
Metallothionein &Cadmium Carcinogenesis in the ProstateR01CA062269 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HO, SHUK-MEI · 1995 to 2006
$1.4M
TOXICANT OR AGING INDUCED OXIDATIVE STRESS IN PROSTATER01AG013965 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HO, SHUK-MEI · 1997 to 2000
$229k
NCI NIH HHS CA15776NCI NIH HHS CA62269NCI NIH HHS R01 CA015776NCI NIH HHS R01 CA062269NIA NIH HHS AG13965
6 · The paper itself

Abstract

Although the functional role of TRPM-2/clusterin in the prostate remains controversial, it has been postulated that transcriptional activation of the gene is an important mechanism in castration-induced prostatic involution and perhaps is a means for prostatic cells to escape apoptotic induction. In the present study, we have measured expression levels of TRPM-2/clusterin and apoptotic activities in the prostates of castrated Noble (NBL) rats and those treated with testosterone (T) and estradiol-17beta (E2) for 16 weeks. We have previously shown that the combined sex hormone treatment (T+E2) induces dysplasia, a purported preneoplastic lesion, exclusively in the dorsolateral prostates (DLPs) of all treated rats. In the present study, we demonstrate that, as expected, castration readily induced enhanced TRPM-2/clusterin expression, which was accompanied by increased apoptotic activity in the epithelia of DLP and ventral prostate (VP). The increase in TRPM-2/clusterin expression appeared earlier and was more dramatic in the VP than in the DLP. In sharp contrast, treatment of rats with T+E2 for 16 weeks induced augmentation of TRPM-2/clusterin expression selectively in the dysplastic lesions of the DLP but not in the lesion-free VP. The enhanced expression of TRPM-2/clusterin in the dysplastic epithelium was, however, not attended by an increase in apoptotic activity within the lesion. Thus, the observed up-regulation of TRPM-2/clusterin expression in the dysplastic foci of T+E2-treated rats occurred in animals whose androgen status remained normal and, despite the increased level of expression of this gene, apoptotic activity in these lesions was unchanged from basal values measured in the DLPs of untreated rats. These findings suggest that TRPM-2/clusterin expression in dysplastic lesions was no longer repressed by androgen nor was it associated with apoptosis. We propose that overexpression of the gene is likely a phenotype of neoplastic transformation. In addition, we speculate that TRPM-2/clusterin may serve as a survival factor, which could favor accumulation of transformed cells in dysplastic foci and thus promote the carcinogenic process.

Indexed as

ApoptosisMolecular ChaperonesAnimalsClusterinEstradiolGlycoproteinsImmunoenzyme TechniquesIn Situ HybridizationMaleOrchiectomyProstateProstatic DiseasesRatsRNA, MessengerTestosteroneClusterinEstradiolGlycoproteinsMolecular ChaperonesRNA, MessengerTestosterone

Identifiers

PMID9665473
PMCPMC1852960
OpenAlexW2133305199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.